Should Oxaliplatin Be Added to Preoperative Chemoradiation?

  • Carlo Aschele
  • Elisa Bennicelli
  • Amalia Milano


Oxaliplatin radiosensitizes human colon carcinoma cells in preclinical models, and it has been shown to improve the efficacy of fluoropyrimidines (FPs) in the treatment of metastatic and radically resected, early-stage colon cancer. Its combination with 5-fluorouracil (FU) and radiation in the preoperative treatment of rectal cancer may thus result in improved control of micrometastases at distant sites and increased local tumor shrinkage before surgery. High rates of tumor sterilization at surgery were indeed observed in multiple phase I–II studies testing the combination of oxaliplatin with FPs and preoperative radiation, particularly when a weekly schedule was used for oxaliplatin administration. Seven randomized trials have then been launched to investigate the addition of oxaliplatin to preoperative radiation and concomitant fluorouracil or capecitabine. Safety and activity data have now been reported. The results consistently indicate that adding oxaliplatin to a fluoropyrimidine does not improve primary tumor response to preoperative chemoradiation with only one study showing a statistically significant, but limited, improvement in the rate of complete tumor sterilization at surgery and other measures of response to neoadjuvant chemoradiation similarly distributed between the groups treated with or without oxaliplatin in all of these studies. Conversely, toxicity was significantly increased when oxaliplatin was added to standard, FP-based preoperative chemoradiation. Data on clinical outcome have been so far published for four out of seven studies and show a small improvement in 3- or 5-year DFS that reaches statistical significance in only one study. There was no impact on local control, while distant metastases were slightly reduced in the three studies reporting on this endpoint (with statistical significance in one of them). While further follow-up of these trials and clinical outcome data of STAR-01 and PETACC-6 are awaited to fully understand the role of oxaliplatin added to preoperative chemoradiation, alternative strategies are being developed to incorporate oxaliplatin in the preoperative treatment of locally advanced rectal cancer, including neoadjuvant chemotherapy before chemoradiation and consolidation chemotherapy in the interval between chemoradiation and surgery.


  1. 1.
    Allegra CJ, Yothers G, O’Connel MJ et al (2015) Neoadjuvant 5-FU or Capecitabine plus radiation with or without Oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 107(11):djv248CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRefPubMedGoogle Scholar
  3. 3.
    Aschele C, Lonardi S (2007a) Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer. J Clin Oncol 25:602–603CrossRefPubMedGoogle Scholar
  4. 4.
    Aschele C, Lonardi S (2007b) Multidisciplinary treatment of rectal cancer: medical oncology. Ann Oncol 18:1908–1915CrossRefPubMedGoogle Scholar
  5. 5.
    Aschele C, Friso ML, Pucciarelli S et al (2005) A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16:1140–1146CrossRefPubMedGoogle Scholar
  6. 6.
    Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780CrossRefPubMedGoogle Scholar
  7. 7.
    Blackstock AW, Hess S, Chaney S et al (1999) Oxaliplatin: in vitro evidence of its radiation sensitizing activity. Pre-clinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 45:253–254CrossRefGoogle Scholar
  8. 8.
    Cividalli A, Ceciarelli F, Livdi E et al (2002) Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 52:1092–1098CrossRefPubMedGoogle Scholar
  9. 9.
    De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947CrossRefPubMedGoogle Scholar
  10. 10.
    Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 28:859–865CrossRefPubMedGoogle Scholar
  11. 11.
    Francois E, Gourgou-Bourgade S, Azria D et al (2016) ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: results after 5 years of follow-up. J Clin Oncol 34(suppl 4S):abstr 490CrossRefGoogle Scholar
  12. 12.
    Freyer G, Bossard N, Romestaing P et al (2001) Addition of oxaliplatin to continuous fluorouracil l-folinic acid and concomitant radiotherapy in rectal cancer: the Lyon R97-03 phase I trial. J Clin Oncol 19:2433–2438CrossRefPubMedGoogle Scholar
  13. 13.
    Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16(8):957–966CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gérard JP, Chapet O, Nemoz C et al (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0–04 phase II trial. J Clin Oncol 21:119–1124CrossRefGoogle Scholar
  15. 15.
    Gérard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30(36):4558–4565CrossRefPubMedGoogle Scholar
  16. 16.
    Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15(11):1245–1253CrossRefPubMedGoogle Scholar
  17. 17.
    Jiao D, Zhang R, Gong Z et al (2015) Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cance Res 27(6):588–596Google Scholar
  18. 18.
    Lonardi S, Cionini L, Di Fabio F et al (ASCO 2016). Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer. J Clin Oncol 34, 2016 (suppl; abstr e15149)Google Scholar
  19. 19.
    Methy N, Bedenne L, Conroy T et al (2010) Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 21:518–524CrossRefPubMedGoogle Scholar
  20. 20.
    Nagtegaal ID, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312CrossRefPubMedGoogle Scholar
  21. 21.
    Rödel C, Liersch T, Hermann RM et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25(1):110–117CrossRefPubMedGoogle Scholar
  22. 22.
    Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679–687CrossRefPubMedGoogle Scholar
  23. 23.
    Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16(8):979–989CrossRefPubMedGoogle Scholar
  24. 24.
    Ryan DP, Niedzwiecki D, Hollis D et al (2006) Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiationtherapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 24:2557–2562CrossRefPubMedGoogle Scholar
  25. 25.
    Schmoll HJ, Haustermans K, Price TJ et al (2014) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis. Proc Am Soc Clin Oncol 32:5s. (abstr 3501)Google Scholar
  26. 26.
    Sebag-Montefiore D, Glynne-Jones R, Falk S et al (2002) Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 21:146a. (abstr 580)Google Scholar
  27. 27.
    Valentini V, De Paoli A, Barba MC, et al (2014) Capecitabine based preoperative chem-RT in rectal cancer intensified by RT or Oxaliplatin: the INTERACT trial ESTRO abstr OC-0494Google Scholar
  28. 28.
    Yothers G, O’Connell MJ, Allegra CJ et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29(28):3768–3774CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Carlo Aschele
    • 1
  • Elisa Bennicelli
    • 1
  • Amalia Milano
    • 1
  1. 1.Medical Oncology – Ospedale Sant’AndreaLa SpeziaItaly

Personalised recommendations